NEW YORK (GenomeWeb) – Roche said late on Tuesday that Pathology Inc. has become a Roche Molecular Center of Excellence for the next five years.

With the designation, Pathology's molecular diagnostic laboratory will be able to offer molecular technologies from Roche, such as the US Food and Drug Administration-approved cobas HPV test, to physicians and patients. The test helps clinicians assess a patient's risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.